Join Us for the Genetic Medicine Workshop!
Date: January 24, 2026 @ 9:00 am – @ 2:30 pm
Location: 1633 Old Bayshore Hwy #280, Burlingame, CA 94010
Join leading experts from biotech and pharma for a dynamic workshop on the future of RNA and DNA therapeutics. Discover cutting-edge advances in LNP delivery, RNA drug development, AI-powered gene editing, and next-generation nucleic acid platforms, and gain actionable insights driving the next wave of genetic medicines. Register now!
Agenda
Speakers’ Bios
Jingjing Zhou
Vice President, Cosychem
Dr. Zhou is currently the Vice President of Technology at Cosychem, where he leads cutting-edge efforts in oligonucleotide synthesis, lipid nanoparticle delivery systems, and the upstream development of raw materials critical to RNA and DNA therapeutics.
He earned his Ph.D. from Peking University, where he laid the foundation for his research in chemical biology and biomolecular engineering. Following that, he completed his postdoctoral training at the University of California, San Diego, deepening his expertise in translational biochemistry and nucleic acid drug development.
With extensive hands-on experience building GMP-compliant platforms and leading global technical collaborations, Dr. Zhou is at the forefront of developing integrated solutions for the next generation of nucleic acid-based medicines.
Lijun Huang
Former senior principal scientist at Poseida Therapeutics of Genentech
Dr. Lijun Huang is a medicinal chemist and nucleic-acid delivery scientist with extensive experience in ionizable lipid design, targeted LNP platforms, and oligonucleotide chemistry. He has developed novel lipids, GalNAc and cleavable PEG-lipid conjugates that have progressed into NHP and preclinical studies, supporting siRNA, mRNA, DNA and gene-editing programs. Dr. Huang has led cross-functional collaborations with CROs/CMOs on scale-up, CMC documentation, and analytical characterization of LNPs. His current work focuses on advancing targeted LNPs—including antibody- and VHH-decorated systems—for in vivo cell engineering and next-generation RNA therapeutics.
Kai-Yuan Chen
Director, Computational Genomics and Data Science, Scribe Therapeutics
Kai-Yuan Chen, PhD, is the Director of Computational Genomics and Data Science at Scribe Therapeutics, where he leads cross-functional teams spanning computational biology, genomics, data science, and lab automation. His work focuses on integrating high-throughput genomics with advanced ML/AI modeling to accelerate development of next-generation CRISPR-based gene and epigenetic editing therapies.
Ivy Fu
Senior Scientist in RNA Drug Research and Development, Eurofins
Dr. Ivy Fu holds a Ph.D. in Pharmacy and completed her postdoctoral training at the University of Utah, where she built broad expertise in drug discovery, IND-enabling studies, and translational research. Her work contributed to the discovery of a potential therapeutic candidate, which led to a patent application and supported the launch of the startup NephroNovus.
She is now a Senior Scientist at Eurofins, specializing in assay optimization, candidate evaluation, and the development of novel therapeutics across multiple modalities and disease areas. Her contributions have directly supported the advancement of a drug development program into Phase III clinical trials.
With a strong foundation in scientific innovation and translational impact, Dr. Fu is dedicated to bridging research with real-world therapeutic development.
Sponsored By:
.